title: Cyclic and linear peptides derived from alpha-amylase inhibitory protein tendamistat.
abstract: Tendamistat is a strong inhibitory protein of porcine pancreatic alpha-amylase (PPA) with a K(i) value of 0.2 nM. To develop potent alpha-amylase inhibitors, we synthesized six odd-length cyclic peptides (5-15 residues) and four even-length cyclic peptides (10 and 12 residues) having the inhibitory sequence of tendamistat. Their PPA inhibitory activities were evaluated, and, among them, the 11-residue cyclic peptide Ten(15-23) (K(i) = 0.27 microM) exhibited the strongest inhibitory activity (K(i) = 0.27-1.41 microM). To examine the effect of cyclic structure on PPA inhibition, ten linear peptides corresponding to the cyclic peptides were also synthesized, and their PPA inhibitory activities were evaluated (K(i) = 0.28-1.00 microM). Interestingly, the 11-residue linear peptide Ten(15-23) exhibited almost the same inhibitory activity (K(i) = 0.28 microM) as that of cyclic Ten(15-23). The results of a circular dichroism study indicated that stabilization of the beta-hairpin structure occurred only for cyclic Ten(15-23). Also, the results of proteolytic digestion experiments of the cyclic and linear Ten(15-23) peptides by trypsin and chymotrypsin suggested no differences in protease resistance between the cyclic and linear structures. Therefore, we demonstrated that both cyclic and linear peptides containing the inhibitory sequence of tendamistat exhibit potent PPA inhibitory activity.
authors.affiliation: Department of System Engineering of Materials and Life Science, Faculty of Engineering, Toyama University, Gofuku, Toyama 930-8555, Japan. shinono@eng.toyama-u.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Ono
authors.forename: M
authors.initials: M
authors.lastname: Umezaki
authors.forename: N
authors.initials: N
authors.lastname: Tojo
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: H
authors.initials: H
authors.lastname: Taniyama
authors.forename: T
authors.initials: T
authors.lastname: Kaneko
authors.forename: T
authors.initials: T
authors.lastname: Fujii
authors.forename: H
authors.initials: H
authors.lastname: Morita
authors.forename: C
authors.initials: C
authors.lastname: Shimasaki
authors.forename: I
authors.initials: I
authors.lastname: Yamazaki
authors.forename: T
authors.initials: T
authors.lastname: Yoshimura
authors.forename: T
authors.initials: T
authors.lastname: Kato
mesh_terms: D000595:Amino Acid Sequence / Q000502:physiology; D000818:Animals; D002918:Chymotrypsin / Q000494:pharmacology; D002942:Circular Dichroism; D004351:Drug Resistance; D006868:Hydrolysis; D020799:Pancrelipase / Q000378:metabolism; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry* / Q000187:drug effects; D013329:Structure-Activity Relationship; D013552:Swine; D014357:Trypsin / Q000494:pharmacology; D000516:alpha-Amylases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D010455:Peptides; D010456:Peptides, Cyclic; D020799:Pancrelipase; D000516:alpha-Amylases; D002918:Chymotrypsin; D014357:Trypsin; C030526:tendamistate